Experts have predicted emerging Indian and Chinese markets will outpace Western markets as the $2.3bn oral solid dosage form (OSDF) excipients global market grows at a sustainable rate.
Pharma firms are returning to European and North American manufacturers as quality issues and rising costs have lost India and China some of its ‘Eastern promise,’ according to industry experts.
The drug industry's need to improve product quality while reducing production costs is driving global demand for testing technologies according to Sepha.
UK-based Sinclair Pharmaceuticals has entered into a manufacturing
and distribution agreement with Wockhardt, an Indian pharmaceutical
and biotech company.
Despite the challenges that emerging market present, such as
intellectual property (IP) exposure and drug pricing controls, the
pharma industry is not being deterred.